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Abstract
Objective: Atherosclerosis may lead to acute clinical events by rupture of a vulnerable atherosclerotic plaque. Previously, we demonstrated
that peptidoglycan (PGN), a major cell wall component of gram-positive bacteria that induces production of proinflammatory cytokines through
TLR2 and CD14, is prevalent in atherosclerotic lesions with histological features associated with plaque vulnerability. We hypothesized that in
atherosclerotic patients antibody levels against PGN may differ compared with matched controls. Methods and results: ELISA was performed
to measure immunoglobulin levels against PGN in sera of 80 atherosclerotic patients versus 77 control patients with an increased cardiovascular
risk, frequency-matched for age, sex and risk factors for atherosclerotic disease. In all patients and controls, intima-media (IMT) thickness was
assessed using an array transducer. Significantly lower levels of IgM directed against PGN were found in atherosclerotic patients compared with
the control patients without clinically manifested disease (P = 0.02). The IgM levels against PGN decreased with increasing mean common
carotid IMT thickness (P = 0.006). Conclusions: These results show that patients suffering from atherosclerotic disease have decreased IgM
levels against PGN. The data suggest that an antibody response against PGN could have a protective effect against the development or activity
of atherosclerotic disease.
© 2004 Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
Atherosclerosis is a chronic inflammatory disease [1].
During the inflammatory response mediators such as
chemokines, cytokines and growth factors are released.
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These mediators are able to recruit inflammatory cells such
as T-lymphocytes and macrophages to the site of injury [2].
Peptidoglycan (PGN) may promote chronic inflammation
at non-mucosal sites [3]. This antigen is present in the cell
walls of most bacteria and is the major constituent (30–70%)
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of gram-positive cell walls. PGN surrounds the cell and
gives strength to withstand the turgor pressure exerted by
the cytoplasm. During gram-positive infections, PGN can
activate granulocytes [4] and upregulate the expression of
adhesion molecules on endothelial cells [5]. PGN can induce
polyclonal antibody formation in peripheral blood mononu-
clear cells of healthy donors dependent on the presence of
T-lymphocytes and monocytes [6]. Furthermore, PGN is
able to induce production of pro-inflammatory cytokines
such as IL-1, IL-6 and TNF- by monocytes/macrophages
in vitro through engagement of toll-like receptor 2 (TLR2)
and CD14 [7,8]. These macrophages are crucial in lipid
metabolism and the development of atherosclerotic le-
sions [9]. Recently, we demonstrated that PGN is present
in atherosclerotic plaques with histological features of a
vulnerable plaque phenotype [10]. Furthermore, PGN may
play a role in the pathogenesis of rheumatoid arthritis,
which also is a chronic inflammatory disease [11,12]. In
view of the postulated functional roles of antibodies against
self antigens in atherosclerosis, we hypothesized that lev-
els of antibodies directed against PGN may be different in
atherosclerotic patients as compared to matched controls. In
the present study, we determined systemic antibody levels
against PGN in patients with severe atherosclerotic disease
and compared these levels to those in a control group with-
out clinically manifest disease. Furthermore, we examined
a possible relation between the immune response against
PGN and the extent of atherosclerotic disease using duplex
wall thickness measurements of the carotid artery.
2. Methods
2.1. Patients
All patients were participants of the Second Manifes-
tations of ARTerial disease (SMART) study; an ongoing,
single-center, prospective cohort study of approximately
3500 patients referred to the University Medical Center
Utrecht for the first time because of atherosclerotic vascular
disease or treatment of atherosclerotic risk factors [13]. The
study was approved by the ethics committee of the Univer-
sity Medical Center Utrecht, and written informed consent
was obtained from all participants.
Eighty atherosclerotic patients that fulfilled all of the fol-
lowing three criteria were selected: (1) a history of clinically
manifest atherosclerotic disease; (2) atherosclerotic disease
at the time of hospital-entry and (3) one cardiovascular risk
factor (hypertension, diabetes mellitus or hyperlipidemia).
Patients were additionally screened for the presence of clini-
cally silent atherosclerotic lesions in the carotid and femoral
arteries and aorta using three approaches. First, atheroscle-
rotic luminal narrowing in the femoral artery was evaluated
by measuring the ratio of the systolic blood pressure mea-
sured at the ankle to the systolic blood pressure measured in
both arms (ankle-brachial pressure index, ABPI). When pa-
tients had a lowered ABPI (≤0.9) they were classified as hav-
ing silent atherosclerosis. Second, stenosis of the common
and internal carotid arteries was measured bilaterally with
Doppler-assisted duplex scanning. When carotid stenosis ex-
ceeded 70%, patients were diagnosed having clinically silent
atherosclerosis. Third, ultrasonography of the abdomen was
performed to measure the anteroposterior juxtarenal diame-
ter and the distal anteroposterior diameter of the aorta. When
distal anteroposterior diameter ≥3 cm or ≥1.5 times antero-
posterior juxtarenal diameter, patients were diagnosed hav-
ing clinically silent atherosclerosis.
Seventy-seven control patients from the SMART study
were frequency-matched for sex, age and one of three ma-
jor risk factors (hypertension, diabetes mellitus and hyper-
lipidemia). These patients revealed neither clinically evident
nor silent atherosclerosis.
2.2. Isolation of PGN from human intestinal flora
PGN was prepared from faeces of a healthy subject [14].
In short, homogenized faeces was filtrated and centrifuged
for 45 min at 5000× g. Four volumes of 96% ethanol were
added and after 2 h the precipitate was centrifuged for 15 min
at 5000× g. After dissolving in Milli-Q the suspension was
centrifuged for 1 h at 100,000×g. Size exclusion chromatog-
raphy was done on the clear supernatant using dilutions
of 15–60 mg/30 ml. Collected fractions containing carbohy-
drates but no proteins were pooled, dialyzed and lyophilized.
About 50 mg PGN could be retrieved from 100 g of faeces.
This represents a full representation of the multitude of bac-
terial species occurring in the normal intestinal flora. Since
PGN structure varies from one bacterial species to another,
PGN derived from the full flora provides a broad range of
PGN structures.
2.3. Enzyme-linked immunosorbent-assay (ELISA) for
anti-PGN level
The direct ELISA with faeces PGN coated to microtiter
wells to measure anti-PGN level has been developed and
validated previously [11,15]. As a reference for calculat-
ing antibody levels against PGN, a pooled standard serum
(≈500 bloodbank donors) selected for high anti-PGN reac-
tivity was used. In microtiter plates 50l, 10g/ml PGN
diluted in PBS was coated overnight at 50 ◦C. One hundred
microliter serum diluted in PBS/Tween 0.2% was added and
incubated for 1 h at 37 ◦C. Dilutions of 1:400, 1:1600 and
1:200 were used for IgM, IgG and IgA measurements, re-
spectively. Peroxidase conjugated rabbit anti-human IgM,
IgG or IgA (Jackson Immunoresearch, Inc., Westgroove, PA)
diluted in PBS/Tween 0.2% was used as secondary antibody
during 1 h at 37 ◦C. The development of the colorimetric as-
say took place in the dark for 10–20 min after the addition
of 100l of substrate with ortho-phenylene diamine/H2O2.
The reaction was stopped by adding 50l 4 M H2SO4. Opti-
cal density was measured at 492 nm. On each plate the stan-
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dard serum was included and the background absorption of
the conjugate was tested in duplicate. Levels of antibodies
were expressed as a ratio calculated as follows:
ratio = ODsample − ODbackground
ODstandard serum − ODbackground
2.4. Total immunoglobulin determination
To examine whether total immunoglobulin concentrations
were in the normal range, total IgM and IgG concentrations
of all patients were measured using immunoephelometry ac-
cording to routine and validated clinical chemistry protocols.
2.5. Risk score
Previously, a risk score based on data of pre-existing
disease and risk factors available in the SMART cohort
(SMART risk score) was developed and validated by com-
paring the SMART risk score to the Framingham risk score
and the EPOZ risk score [16]. The three risk scores strongly
correlated with each other. Single points were given for male
gender, age, cardiovascular risk factors, and history and pres-
ence of cardiovascular disease, to a maximum of 24 points
(Table 1). If more than two risk indicators were missing, the
risk score was classified as missing (n = 9 patients). If two
or fewer risk indicators were missing, the missing indicator
was given zero points (n = 1 patient).
2.6. Intima-media thickness measurement
In all patients intima-media thickness (IMT) was mea-
sured in the left and right common carotid arteries as a
measure for the extent of atherosclerosis. Arteries were
examined in anterolateral, posterolateral and mediolateral
direction using an ATL Ultramark 9 machine (Advanced
Technology Laboratories, Bethel, WA) equipped with a
10 MHz linear array transducer. The intima-media surface
of the selected area was calculated on-line using built-in
software of the ultrasound system. The mean IMT of the six
measurements in each patient was calculated. Investigators
who performed the ELISAs were blinded for the outcome
of IMT measurements.
2.7. Statistical analysis
A Mann–Whitney test was used to compare the ratios
of IgM, IgG and IgA measured in the PGN–ELISA of the
atherosclerotic patients and the control group versus stan-
dard serum. All patients were divided into quartiles on the
basis of IMT or SMART risk score. Differences in IgM lev-
els against PGN between the quartiles were measured with
one-way ANOVA and a Tukey post hoc multiple compari-
son. All values are presented as mean ± standard error of
mean (S.E.M.). A P-value of <0.05 was considered signif-
icant.
Table 1
SMART risk score based on pre-existing vascular disease and risk factors
Indicator Points
Demographic characteristics
Male gender 1
Age ≥ 30 1
Age ≥ 40 1
Age ≥ 50 1
Age ≥ 60 1
Age ≥ 70 1
Risk factors
Body mass index ≥ 30 1
Smoking, current or past 1
Hyperlipidemiaa 1
Medication for indication hyperlipidemia 1
Hyperglycemiab 1
Medication for indication diabetes mellitus 1
Hypertensionc 1
Medication for indication hypertension 1
History of vascular disease
Angina pectoris 1
Myocardial infarction 1
Transient ischaemic attack or stroke 1
Carotid endarterectomy 1
Intervention on leg arteriesd 1
Aortic aneurysmectomy 1
Existing vascular disease
Peripheral arterial diseasee 1
Internal carotid artery stenosis ≥ 50%f 1
Abdominal aortic aneurysmg 1
Renal failureh 1
a Total cholesterol ≥6.5 mmol/l, triglycerides ≥2.3 mmol/l, or
HDL-cholesterol ≥1.0 mmol/l.
b Fasting serum glucose ≥7.0 mmol/l or non-fasting serum glucose
≥11.1 mmol/l.
c Systolic pressure ≥160 mmHg or diastolic pressure ≥95 mmHg.
d Every vascular intervention on the aorta, iliacal, femoral and crural
arteries.
e Resting ABPI ≤0.90 or post exercise ABPI decreasing ≥20% in at
least one leg.
f Peak systolic velocity >150 cm/s corresponding with diameter reduc-
tion ≥50% on at least one leg.
g Distal anteroposterior diameter ≥3 cm or ≥1.5 times the anteropos-
terior juxtarenal diameter.
h Serum creatinine >120mol/l or microalbuminuria >20 mg/mmol.
3. Results
3.1. Systemic antibody level against PGN in
atherosclerotic patients
The study population consisted of 80 atherosclerotic pa-
tients (40 males, 40 females; mean age 60, range 31–79) and
77 sex-, age-, and risk- factor-matched control patients with-
out clinically manifest disease (38 males, 39 females; mean
age 58, range 32–76). Forty, thirty-one and six atheroscle-
rotic patients entered the hospital with asymptomatic carotid
stenosis, peripheral arterial disease and abdominal aortic
aneurysm, respectively. Furthermore, 5, 7 and 68 atheroscle-
rotic patients suffered from hypertension, diabetes and hy-
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Table 2
Characteristics of the study population
Characteristics of the study population Controls Cases
Total number 77 80
Age (years) 57.5 59.7
Women (%) 49 50
Body mass index (kg/m2) 26.1 26.1
Smoking (%) 29 50
Mean common carotid intima-media
thickness (cm)
0.078 0.104
SMART risk score 6.77 9.96
perlipidemia, respectively. In Table 2, the baseline charac-
teristics of the study population are presented. The data in-
dicate that atherosclerotic patients have significantly lower
IgM antibody levels against PGN compared to control pa-
tients (0.527 ± 0.037 versus 0.630 ± 0.039 P = 0.02). No
differences were observed in IgG and IgA antibody levels
against PGN in atherosclerotic patients compared to con-
trol patients (0.400 ± 0.023 versus 0.348 ± 0.023 P = 0.1
for IgG and 0.853 ± 0.074 versus 0.932 ± 0.079 P = 0.4
for IgA, respectively). Total IgM and IgG immunoglobulin
concentrations of the control patients were not significantly
different from atherosclerotic patients (1.26± 0.07 g/l ver-
sus 1.09 ± 0.07 g/l, P = 0.1 and 9.93 ± 0.34 g/l versus
10.13 ± 0.28 g/l, P = 0.6, respectively). Furthermore, no
relation between IgM, IgG and IgA antibody levels against
PGN and age was observed (P = 0.07, 0.9 and 0.2, re-
spectively). In the same patient cohort at another timepoint,
measurement of IgM levels against PGN could be repro-
duced (0.711± 0.055 versus 0.860± 0.057, atherosclerotic
patients versus control patients P = 0.03). For repeat ex-
periments both primary optical density readings as well as
ratio of patient over reference signals were ranked for all
patients. No differences between the experiments were ob-
served in the rankings, demonstrating that the experiments
were comparable and the data reproducible.
3.2. Antibody titers against PGN in relation to IMT and
SMART risk score
Fig. 1 presents the association between common carotid
IMT and IgM antibody level against PGN in all patients.
The cut-off values of the IMT run from 0.05 to 0.06 cm in
quartile 1, from 0.07 to 0.09 cm in quartile 2, from 0.10 to
0.12 cm in quartile 3 and from 0.13 to 0.15 cm in quartile 4.
The IgM level against PGN decreased with increasing mean
IMT (P = 0.006); the P for trend is 0.008.
The decrease was significant between the first and third
and between the first and fourth quartile (P = 0.02 and
0.004, respectively). After normalization of the specific IgM
response against PGN to the total IgM response, a decrease
could still be observed with increasing IMT (P = 0.009). At
the second time point these data could be reproduced. The
IgM level against PGN decreased with increasing mean IMT
(P = 0.001). Between the first and third and between the
Fig. 1. IgM level against peptidoglycan (PGN) in relation to common
carotid intima-media thickness (IMT). The IgM level against PGN de-
creased with increasing IMT (R2 = 0.0537, P = 0.006, P for trend is
0.008). The decrease was significant between the first and third and first
and fourth quartile (∗P = 0.02 and ∗∗P = 0.004).
Fig. 2. IgM level against PGN in relation to SMART risk score. The
SMART risk score showed an inverse relation with IgM levels against
PGN (R2 = 0.0834, P = 0.003, P for trend is <0.001). Differences were
significant between the first and second, first and third and first and fourth
quartiles (∗P = 0.003, ∗∗P = 0.003 and ∗∗∗P < 0.001).
first and fourth quartile, this decrease was again significant
(P = 0.01 and 0.009, respectively).
Fig. 2 demonstrates the relationship between IgM levels
against PGN and the SMART risk score in all patients. The
IgM level against PGN decreased with increasing SMART
risk score (P = 0.003); the P for trend is <0.001. The sig-
nificant decrease in IgM levels against PGN was due to sig-
nificant differences between the first and second, first and
third and between the first and fourth quartiles (P = 0.003,
0.003 and P<0.001, respectively). Again after normaliza-
tion of the specific IgM response against PGN to the total
IgM response, the IgM response decreased with increasing
SMART risk score (P = 0.02).
4. Discussion
Previously, we have demonstrated that the bacterial cell
wall component PGN is present in atherosclerotic plaques
[10]. Since individual systemic immunoglobulin isotypes are
involved in the process of immune exclusion, i.e. prevention
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of redistribution of microbial antigens from the mucosa to
other sites in the body [17], we hypothesized that atheroscle-
rotic patients may differ from matched controls in their levels
of antibodies directed against PGN. We indeed observed that
atherosclerotic patients had a significantly lower systemic
IgM antibody level against PGN than control patients closely
matched for risk factors, but comparable IgG and IgA. In
addition, the level of IgM antibodies against PGN nega-
tively correlated with common carotid IMT and a risk score
for atherosclerotic disease, suggesting a functional relation-
ship. The results show that there is no statistically significant
difference in total IgM concentration. There was however
a trend towards a decrease in total IgM in atherosclerotic
patients as well as a trend toward a decrease in IgM levels
against PGN with age. Since these trends might partly ex-
plain the lowered IgM PGN titers we also normalized the
specific IgM to the total IgM. After normalization a decrease
in IgM levels could still be observed with increasing com-
mon carotid IMT and SMART risk score.
There are three obvious interpretations of these findings:
first, the decrease in antibody levels to PGN in atheroscle-
rotic patients might be due to a generalized depression of
antibody levels. However, as mentioned earlier, even after
correction for total IgM the difference in IgM levels against
PGN among groups was still evident. Second, decreased
IgM antibody levels against PGN might be explained by de-
creased exposure to the antigen. This possibility is hard to
address, but seems unlikely with respect to the ubiquitous na-
ture of PGN, being present at high level in all gram-positives
and low level in gram-negatives to which we are continu-
ously exposed at all mucosa, including the healthy intestinal
and skin flora. The unaltered levels of IgG and IgA specific
for PGN also argue against this option. And third, the de-
creased IgM levels may reflect an increased consumption of
anti-PGN IgM antibodies, caused by binding to intact bacte-
ria or cell wall fragments with subsequent immune complex
formation and enhanced removal.
To our knowledge, this is the first study that has examined
the relationship between the presence of immunoglobulins
against PGN and atherosclerosis. Other studies also demon-
strated significantly lower titers of IgM against oxidized
LDL (Ox-LDL), a key autoantigen with neo-epitopes, in
patients with a history of atherosclerosis, as well as nega-
tive associations between levels of IgM Ox-LDL antibodies
and IMT [18,19]. Another study indicated that low IgM
and IgG antibody levels against Ox-LDL may be associ-
ated with the presence of major risk factors for developing
atherosclerotic disease [20]. These results support the con-
cept that a lowered antibody response to proinflammatory
antigens like PGN or Ox-LDL may be causally related to
the activity of atherosclerotic disease.
In a few other studies, immunization with Ox-LDL
was found to be correlated with inhibition of the progres-
sion of atherosclerosis. In mice and rabbits, it has been
demonstrated that immunization with Ox-LDL leads to in-
creased immunoglobulin levels and immunization with both
Ox-LDL and HSP-65 inhibits progression of atherosclero-
sis [21,22]. Furthermore, Caligiuri et al. [23] suggest that
protection from atherosclerosis is associated with specific
antibody responses to Ox-LDL, developing in the spleen.
This is further supported by Witztum and coworkers [24]
who reported that IgM antibodies reactive to phosphoryl-
choline are deposited in atherosclerotic lesions, can recog-
nize Ox-LDL and block its uptake by macrophages. These
results suggest that an immune response against (auto)
antigens has a protective effect against the development of
atherosclerotic lesions. In this study, we showed the op-
posite, a lowered immune response to the antigen PGN is
associated with more pronounced atherosclerotic disease.
While Ox-LDL and HSP-65 are auto-antigens, PGN is the
first exogenous antigen that shows a negative correlation
between specific IgM and atherosclerotic activity. How-
ever, the role of the immune system in the pathogenesis of
atherosclerosis is complex [25]. Therefore, we can not con-
clude that all increased antibody responses are protective,
while decreased antibody responses are pro-atherogenic.
In atherogenesis, the earliest changes are observed in the
subendothelial matrix where fatty streaks develop with the
invasion of monocytes, T-lymphocytes and smooth muscle
cells. The fatty streak progresses into an advanced lesion
with necrotic core formation that is covered by a fibrous
cap. Eventually a plaque can rupture, leading to unstable
coronary syndromes or myocardial infarction (MI). Previ-
ously, we studied PGN expression in advanced lesions [10]
and demonstrated that PGN is present in lesions with an
inflammatory, vulnerable, plaque phenotype. In this study,
we found that in atherosclerotic patients the IgM antibody
levels against PGN are significantly lower compared to the
control patients, suggesting that the presence of PGN is as-
sociated with a decreased IgM antibody titer against PGN.
It is unknown whether the results of the present study can be
applied not only to advanced lesion formation but also to the
early stages of atherosclerotic disease. It is highly likely that
any control population will also hide early stage atheroscle-
rotic lesions so this answer will probably be given by post
mortem studies in which non-atherosclerotic segments need
to be investigated for the presence of PGN.
Other research groups showed previously that PGN may
play a role in the pathogenesis of rheumatoid arthritis, which
also is a chronic inflammatory disease [11,12]. In these stud-
ies rheumatoid arthritis patients had significantly lower sys-
temic IgG antibody levels against PGN compared to healthy
controls.
Previous studies suggest that an association exists be-
tween chronic infection with Chlamydia pneumoniae and
manifestations of coronary heart disease (CHD) [26,27]. C.
pneumoniae has been found within atherosclerotic tissues
and high-titer IgG antibodies against C. pneumoniae are as-
sociated with an increased risk of CHD death and MI [28].
Furthermore, few studies have suggested there is a strong
correlation between Helicobacter pylori infection and ad-
verse cardiovascular events or systemic inflammation mark-
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ers [29,30]. Most attention has been paid to the potential role
of gram-negative bacteriae, like C. pneumoniae, in athero-
genesis and the occurrence of adverse events. The present
observation suggests that the role of gram-positive bacteriae
and their most recognized ligand, PGN, need to be taken
into account when the role of bacterial load in atherogenesis
is discussed.
In summary, in atherosclerotic patients systemic IgM an-
tibodies against the proinflammatory antigen PGN are sig-
nificantly lower compared to control patients with increased
cardiovascular risk but without clinically manifest disease,
perhaps due to preferential downregulation of the IgM an-
tibody response. This result supports the idea that immune
modulation may affect the progression of atherosclerotic dis-
ease. Further studies are required to assess which mecha-
nism underlies lower IgM levels, and whether IgM directed
against PGN is beneficial for example by reducing its access
to plaques.
This is a cross-sectional study. Therefore, this study can-
not exclude the possibility that the decrease in IgM antibody
levels against PGN is a consequence of the atherosclerotic
process itself. To show that the levels of IgM antibody titers
against PGN are preceding the atherosclerotic process and
thereby contribute to atherosclerosis, prospective studies
need to be performed.
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